COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Cardiac Output Autonomic Stimulation Therapy for Acute Heart Failure (COAST-AHF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03169803
Recruitment Status : Unknown
Verified August 2018 by NeuroTronik Inc..
Recruitment status was:  Recruiting
First Posted : May 30, 2017
Last Update Posted : August 23, 2018
Information provided by (Responsible Party):
NeuroTronik Inc.

Brief Summary:
A feasibility study to investigate the safety and performance of the NeuroTronik Cardiac Autonomic Nerve Stimulation (CANS) Therapy System

Condition or disease Intervention/treatment Phase
Heart Failure Acute Device: NeuroTronik CANS Therapy™ System Not Applicable

Detailed Description:
A single-arm, safety study intended to assess safety and system performance, and the feasibility to improve hemodynamics in patients with acute heart failure syndrome using transvenous, cardiac autonomic nerve stimulation (CANS) therapy. In addition, the effects of NeuroTronik CANS Therapy™ on the congestion of patients will be studied. The study proposes that the NeuroTronik CANS Therapy™ System be deployed during the acute heart failure syndrome hospital admission, along with existing standard treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: Cardiac Output Autonomic Stimulation Therapy for Acute Heart Failure (COAST-AHF) - System Design Study
Actual Study Start Date : May 19, 2017
Estimated Primary Completion Date : May 19, 2019
Estimated Study Completion Date : June 19, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Experimental: Single arm, NeuroTronik CANS Therapy System Device: NeuroTronik CANS Therapy™ System
The NeuroTronik CANS Therapy™ System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.

Primary Outcome Measures :
  1. Arterial blood pressure [ Time Frame: 24 hours ]
  2. Heart Rate [ Time Frame: 24 hours ]

Secondary Outcome Measures :
  1. Cardiac output [ Time Frame: 24 hours ]
  2. Pulmonary capillary wedge pressure [ Time Frame: 24 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Left Ventricular Ejection fraction < 40%, measured in the last year
  2. At least two of the following:

    • Pulmonary Capillary Wedge Pressure > 18 mmHg
    • Pulmonary congestion on Chest X-ray
    • Jugular vein distension
    • Pulmonary rales
    • Edema
    • Dyspnea at rest
    • Two (2) emergency room visits or hospital admissions in the past three (3) months, or three (3) emergency room visits or admissions in the past six (6) months requiring intravenous diuretics, ultrafiltration or in-hospital inotropic therapy.
  3. With or without evidence of low perfusion

Exclusion Criteria:

  1. Systolic Blood Pressure < 90 mmHg or > 160 mmHg
  2. Catecholamine or inotropic therapy within the previous 48 hours
  3. Levosimendan within the previous 72 hours
  4. Chronic outpatient catecholamine or inotropic therapy
  5. Presence of implanted pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy device
  6. Presence of or prior vagal nerve stimulator
  7. Coronary artery bypass graft surgery, percutaneous coronary intervention, acute myocardial infarction, or valve replacement within prior 1 month
  8. Second or third degree heart block
  9. History of atrial or ventricular arrhythmias
  10. History of mitral or aortic valve stenosis or regurgitation
  11. Hypertrophic obstructive or infiltrative cardiomyopathy
  12. Prior vagotomy
  13. Prior heart transplant
  14. Narrow angle glaucoma
  15. Renal failure - either on dialysis or serum creatinine > 2.0 mg/dl
  16. Hepatic failure - bilirubin, serum glutamic oxaloacetic transaminase, or serum glutamic pyruvic transaminase > four times upper limit of normal
  17. Life expectancy < 12 months per physician judgment
  18. Women who are pregnant
  19. Allergy to fentanyl, midazolam, propofol, eggs, egg products, soybeans, or soy products
  20. Subjects unwilling or unable to provide consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03169803

Layout table for location contacts
Contact: Temístocles Díaz, MD +507.204.8354
Contact: Elsa I Abruzzo +1.513.236.0857

Layout table for location information
Hospital Punta Pacífica Recruiting
Panama City, Panama
Contact: Temístocles Díaz, MD    +507.204.8354   
Contact: Elsa Abruzzo    +1.513.236.0857   
Principal Investigator: Temístocles Díaz, MD         
Sponsors and Collaborators
NeuroTronik Inc.
Layout table for investigator information
Principal Investigator: Temístocles Díaz, MD Hospital Punta Pacífica, Panama City, Panama
Layout table for additonal information
Responsible Party: NeuroTronik Inc. Identifier: NCT03169803    
Other Study ID Numbers: 700022-01
First Posted: May 30, 2017    Key Record Dates
Last Update Posted: August 23, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by NeuroTronik Inc.:
Electrical Stimulation Therapy
Parasympathetic Nervous System
Sympathetic Fibers
Post Ganglionic
Congestive Heart Failure
Heart Failure
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases